losartan has been researched along with Neurofibromatosis 2 in 1 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Neurofibromatosis 2: An autosomal dominant disorder characterized by a high incidence of bilateral acoustic neuromas as well as schwannomas (NEURILEMMOMA) of other cranial and peripheral nerves, and other benign intracranial tumors including meningiomas, ependymomas, spinal neurofibromas, and gliomas. The disease has been linked to mutations of the NF2 gene (GENES, NEUROFIBROMATOSIS 2) on chromosome 22 (22q12) and usually presents clinically in the first or second decade of life.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, L | 1 |
| Vasilijic, S | 1 |
| Sun, Y | 1 |
| Chen, J | 1 |
| Landegger, LD | 1 |
| Zhang, Y | 1 |
| Zhou, W | 1 |
| Ren, J | 1 |
| Early, S | 1 |
| Yin, Z | 1 |
| Ho, WW | 1 |
| Zhang, N | 1 |
| Gao, X | 1 |
| Lee, GY | 1 |
| Datta, M | 1 |
| Sagers, JE | 1 |
| Brown, A | 1 |
| Muzikansky, A | 1 |
| Stemmer-Rachamimov, A | 1 |
| Zhang, L | 1 |
| Plotkin, SR | 1 |
| Jain, RK | 1 |
| Stankovic, KM | 1 |
| Xu, L | 1 |
1 other study available for losartan and Neurofibromatosis 2
| Article | Year |
|---|---|
Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models.
Topics: Animals; Hearing Loss; Humans; Losartan; Mice; Neurilemmoma; Neurofibromatosis 2; Prospective Studie | 2021 |